** Shares of drug developer Entrada Therapeutics TRDA.O rise 7.4% to $14 premarket
** TRDA says FDA has removed clinical hold on co's therapy, ENTR-601-44, which is being studied for a type of muscle-wasting disorder called Duschenne muscular dystrophy (DMD) in the U.S.
** Co receives authorization to initiate early-stage trial
** In December 2022, the FDA placed a clinical hold on co's application to start trials of the therapy
** Co plans to begin study enrollment in H1 2026
** In the last 12 months, TRDA has fallen ~2%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.